These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29633919)

  • 1. Computational study of the binding mechanism between farnesoid X receptor α and antagonist N-benzyl-N-(3-(tertbutyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide.
    Du J; Qiu M; Guo L; Yao X
    J Biomol Struct Dyn; 2019 Apr; 37(6):1628-1640. PubMed ID: 29633919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor.
    Xu X; Xu X; Liu P; Zhu ZY; Chen J; Fu HA; Chen LL; Hu LH; Shen X
    J Biol Chem; 2015 Aug; 290(32):19888-99. PubMed ID: 26100621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation.
    Xu X; Lu Y; Chen L; Chen J; Luo X; Shen X
    Steroids; 2013 Sep; 78(9):813-22. PubMed ID: 23707573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.
    Cruz JN; Costa JFS; Khayat AS; Kuca K; Barros CAL; Neto AMJC
    J Biomol Struct Dyn; 2019 Apr; 37(6):1616-1627. PubMed ID: 29633908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists.
    Song K; Xu X; Liu P; Chen L; Shen X; Liu J; Hu L
    Bioorg Med Chem; 2015 Oct; 23(19):6427-36. PubMed ID: 26337021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of activation mechanism and conformational stability of
    Sivanandam M; Manjula S; Kumaradhas P
    J Biomol Struct Dyn; 2019 Sep; 37(15):4006-4018. PubMed ID: 30301423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.
    Cai SY; Xiong L; Wray CG; Ballatori N; Boyer JL
    Am J Physiol Regul Integr Comp Physiol; 2007 Sep; 293(3):R1400-9. PubMed ID: 17567710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.
    Fiorucci S; Mencarelli A; Distrutti E; Palladino G; Cipriani S
    Curr Med Chem; 2010; 17(2):139-59. PubMed ID: 19941473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.
    Yang L; Broderick D; Jiang Y; Hsu V; Maier CS
    Biochim Biophys Acta; 2014 Sep; 1844(9):1684-93. PubMed ID: 24953769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational insights into the interaction mechanism of transcription cofactor vestigial-like protein 4 binding to TEA domain transcription factor 4 by molecular dynamics simulation and molecular mechanics generalized Born/surface area) calculation.
    Gao J; Zhang Y; Chen H; Chen Q; Feng D; Zhang L; Li C
    J Biomol Struct Dyn; 2019 Jul; 37(10):2538-2545. PubMed ID: 30051771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.
    Xu J; Gu W; Li C; Li X; Xing G; Li Y; Song Y; Zheng W
    J Nat Med; 2016 Jul; 70(3):584-91. PubMed ID: 26968537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X; Wang Y; Wan S; Zhang J
    J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro.
    Howarth DL; Hagey LR; Law SHW; Ai N; Krasowski MD; Ekins S; Moore JT; Kollitz EM; Hinton DE; Kullman SW
    Aquat Toxicol; 2010 Jul; 98(3):245-255. PubMed ID: 20430454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo.
    Mouzannar K; Fusil F; Lacombe B; Ollivier A; Ménard C; Lotteau V; Cosset FL; Ramière C; André P
    FASEB J; 2019 Feb; 33(2):2472-2483. PubMed ID: 30307769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
    Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
    J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
    Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
    J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
    Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
    J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.
    Athanasiou C; Vasilakaki S; Dellis D; Cournia Z
    J Comput Aided Mol Des; 2018 Jan; 32(1):21-44. PubMed ID: 29119352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.